WO2003087159A3 - Modulators of the notch signalling pathway and uses thereof in medical treatment - Google Patents

Modulators of the notch signalling pathway and uses thereof in medical treatment Download PDF

Info

Publication number
WO2003087159A3
WO2003087159A3 PCT/GB2003/001525 GB0301525W WO03087159A3 WO 2003087159 A3 WO2003087159 A3 WO 2003087159A3 GB 0301525 W GB0301525 W GB 0301525W WO 03087159 A3 WO03087159 A3 WO 03087159A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
notch signalling
medical treatment
signalling pathway
notch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/001525
Other languages
French (fr)
Other versions
WO2003087159A2 (en
WO2003087159A8 (en
Inventor
Mark William Bodmer
Emmanuel Cyrille Pascal Briend
Brian Robert Champion
Andrew Christopher Lennard
Grahame James Mckenzie
Tamara Tugal
George Albert Ward
Lesley Lynn Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Ltd
Original Assignee
Lorantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207930A external-priority patent/GB0207930D0/en
Priority claimed from GB0207929A external-priority patent/GB0207929D0/en
Priority claimed from GB0212283A external-priority patent/GB0212283D0/en
Priority claimed from GB0212282A external-priority patent/GB0212282D0/en
Priority claimed from PCT/GB2002/003426 external-priority patent/WO2003011317A1/en
Priority claimed from GB0220912A external-priority patent/GB0220912D0/en
Priority claimed from GB0220913A external-priority patent/GB0220913D0/en
Priority claimed from GB0300234A external-priority patent/GB0300234D0/en
Priority to EP03746366A priority Critical patent/EP1492816A2/en
Priority to AU2003226537A priority patent/AU2003226537A1/en
Priority to JP2003584114A priority patent/JP2006506322A/en
Application filed by Lorantis Ltd filed Critical Lorantis Ltd
Priority to PCT/GB2003/003285 priority patent/WO2004013179A1/en
Priority to EP03766445A priority patent/EP1525221A1/en
Priority to JP2005506075A priority patent/JP2006513260A/en
Priority to AU2003255735A priority patent/AU2003255735A1/en
Priority to EP03748255A priority patent/EP1537145A1/en
Priority to AU2003267563A priority patent/AU2003267563A1/en
Priority to JP2004571915A priority patent/JP2006515177A/en
Priority to PCT/GB2003/003908 priority patent/WO2004024764A1/en
Priority to CA002497226A priority patent/CA2497226A1/en
Publication of WO2003087159A2 publication Critical patent/WO2003087159A2/en
Priority to PCT/GB2004/000046 priority patent/WO2004060262A2/en
Priority to JP2006500232A priority patent/JP2006517533A/en
Priority to EP04704657A priority patent/EP1585543A1/en
Priority to PCT/GB2004/000263 priority patent/WO2004064863A1/en
Publication of WO2003087159A3 publication Critical patent/WO2003087159A3/en
Priority to EP04722319A priority patent/EP1646400B1/en
Priority to AT04722319T priority patent/ATE474593T1/en
Priority to PCT/GB2004/001252 priority patent/WO2004082710A1/en
Priority to US10/958,784 priority patent/US20050220886A1/en
Anticipated expiration legal-status Critical
Priority to US11/050,346 priority patent/US20060002924A1/en
Priority to US11/078,735 priority patent/US20050261477A1/en
Publication of WO2003087159A8 publication Critical patent/WO2003087159A8/en
Priority to US11/188,417 priority patent/US20060204508A1/en
Priority to US11/231,494 priority patent/US20060205823A1/en
Priority to US12/766,738 priority patent/US20100303867A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)

Abstract

A method is disclosed for therapeutic modulation of Notch signalling by administering a construct comprising a multiplicity of bound, linked or immobilised modulators of Notch signalling.
PCT/GB2003/001525 2002-04-05 2003-04-04 Modulators of the notch signalling pathway and uses thereof in medical treatment Ceased WO2003087159A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
EP03746366A EP1492816A2 (en) 2002-04-05 2003-04-04 Modulators of the notch signalling pathway and uses thereof in medical treatment
AU2003226537A AU2003226537A1 (en) 2002-04-05 2003-04-04 Modulators of the notch signalling pathway and uses thereof in medical treatment
JP2003584114A JP2006506322A (en) 2002-04-05 2003-04-04 Internal medicine
JP2005506075A JP2006513260A (en) 2002-08-03 2003-08-01 Complexes of Notch signaling pathway regulators and their use in drug therapy
AU2003255735A AU2003255735A1 (en) 2002-08-03 2003-08-01 Conjugate of notch signalling pathway modulators and their use in medical treatment
PCT/GB2003/003285 WO2004013179A1 (en) 2002-08-03 2003-08-01 Conjugate of notch signalling pathway modulators and their use in medical treatment
EP03766445A EP1525221A1 (en) 2002-08-03 2003-08-01 Conjugate of notch signalling pathway modulators and their use in medical treatment
CA002497226A CA2497226A1 (en) 2002-09-10 2003-09-09 Pharmaceutical compositions and medical treatments comprising notch ligand proteins
PCT/GB2003/003908 WO2004024764A1 (en) 2002-09-10 2003-09-09 Pharmaceutical composition and medical treatments comprising notch ligand proteins
EP03748255A EP1537145A1 (en) 2002-09-10 2003-09-09 Pharmaceutical compositions and medical treatments comprising notch ligand proteins
JP2004571915A JP2006515177A (en) 2002-09-10 2003-09-09 Pharmaceutical composition comprising Notch ligand protein and medical treatment
AU2003267563A AU2003267563A1 (en) 2002-09-10 2003-09-09 Pharmaceutical composition and medical treatments comprising notch ligand proteins
PCT/GB2004/000046 WO2004060262A2 (en) 2003-01-07 2004-01-07 Modulators of notch signalling for use in immunotherpapy
PCT/GB2004/000263 WO2004064863A1 (en) 2003-01-23 2004-01-23 Treatment of autoimmune diseases using an activator for the notch signaling pathway
EP04704657A EP1585543A1 (en) 2003-01-23 2004-01-23 Treatment of autoimmune diseases using an activator for the notch signaling pathway
JP2006500232A JP2006517533A (en) 2003-01-23 2004-01-23 Treatment of autoimmune diseases using activators of the Notch signaling pathway
PCT/GB2004/001252 WO2004082710A1 (en) 2003-03-21 2004-03-22 Treatment of allergic diseases using a modulator of the notch signaling pathway
AT04722319T ATE474593T1 (en) 2003-03-21 2004-03-22 TREATMENT OF ALLERGIC DISEASES USING A MODULATOR OF THE NOTCH SIGNALING PATHWAY
EP04722319A EP1646400B1 (en) 2003-03-21 2004-03-22 Treatment of allergic diseases using a modulator of the notch signaling pathway
US10/958,784 US20050220886A1 (en) 2002-04-05 2004-10-05 Modulators of the Notch signalling pathway and uses thereof in medical treatment
US11/050,346 US20060002924A1 (en) 2002-08-03 2005-02-03 Conjugate of notch signalling pathway modulators and their use in medical treatment
US11/078,735 US20050261477A1 (en) 2002-09-10 2005-03-10 Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US11/188,417 US20060204508A1 (en) 2003-01-23 2005-07-25 Treatment of autoimmune diseases using an activator for the notch signalling pathway
US11/231,494 US20060205823A1 (en) 2003-03-21 2005-09-21 Treatment of allergic diseases using a modulator of the Notch signaling pathway
US12/766,738 US20100303867A1 (en) 2003-03-21 2010-04-23 a composition comprising a notch ligand and an allergenb or allergen bystander antigen

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
GB0207930A GB0207930D0 (en) 2002-04-05 2002-04-05 A method
GB0207929.1 2002-04-05
GB0207929A GB0207929D0 (en) 2002-04-05 2002-04-05 A method
GB0207930.9 2002-04-05
GB0212283A GB0212283D0 (en) 2002-05-28 2002-05-28 A method
GB0212282A GB0212282D0 (en) 2002-05-28 2002-05-28 A method
GB0212282.8 2002-05-28
GB0212283.6 2002-05-28
GBPCT/GB02/03397 2002-07-25
PCT/GB2002/003426 WO2003011317A1 (en) 2001-07-25 2002-07-25 Modulators of notch signalling for use in immunotherapy
GBPCT/GB02/03426 2002-07-25
PCT/GB2002/003397 WO2003012441A1 (en) 2001-07-25 2002-07-25 Method for detecting modulators of notch signalling
GB0220913.8 2002-09-10
GB0220912.0 2002-09-10
GB0220912A GB0220912D0 (en) 2002-09-10 2002-09-10 Medical treatment
GB0220913A GB0220913D0 (en) 2002-09-10 2002-09-10 Medical treatment
GB0300234.2 2003-01-07
GB0300234A GB0300234D0 (en) 2003-01-07 2003-01-07 Medical treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/958,784 Continuation-In-Part US20050220886A1 (en) 2002-04-05 2004-10-05 Modulators of the Notch signalling pathway and uses thereof in medical treatment

Publications (3)

Publication Number Publication Date
WO2003087159A2 WO2003087159A2 (en) 2003-10-23
WO2003087159A3 true WO2003087159A3 (en) 2004-02-05
WO2003087159A8 WO2003087159A8 (en) 2005-05-12

Family

ID=34109266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001525 Ceased WO2003087159A2 (en) 2002-04-05 2003-04-04 Modulators of the notch signalling pathway and uses thereof in medical treatment

Country Status (4)

Country Link
EP (1) EP1492816A2 (en)
JP (1) JP2006506322A (en)
AU (1) AU2003226537A1 (en)
WO (1) WO2003087159A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449303B2 (en) 2003-05-02 2008-11-11 Health Research, Inc. Use of JAG2 expression in diagnosis of plasma cell disorders

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220658D0 (en) * 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
EP1537145A1 (en) * 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
WO2004060262A2 (en) * 2003-01-07 2004-07-22 Lorantis Limited Modulators of notch signalling for use in immunotherpapy
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
WO2004064863A1 (en) * 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
WO2004083372A2 (en) * 2003-03-21 2004-09-30 Lorantis Limited Modulators of the notch signaling pathway immobilized on particles for modifying immune responses
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
CA2546017A1 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
AU2008289462B2 (en) 2007-08-23 2014-01-23 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
KR20110074846A (en) 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 Human Notch-3 based fusion protein as a decoy inhibitor of Notch3 signaling
AR088048A1 (en) 2011-10-04 2014-05-07 Univ Columbia NOTCH1 HUMAN LURE
CA3091158A1 (en) * 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP3826637A4 (en) * 2018-07-26 2022-05-04 The Regents of The University of California TREATMENT OF VASCULAR OCCLUSION BY ACTIVATION OF THE NOTCH SIGNALING PATHWAY
CA3110089A1 (en) * 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
EP3953383A4 (en) * 2019-04-08 2023-01-18 Russell Biotech, Inc. IMPROVED MANUFACTURING PROCESSES FOR CELL-BASED THERAPY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020142A1 (en) * 1996-11-07 1998-05-14 Lorantis Limited Notch
EP0913404A1 (en) * 1996-07-16 1999-05-06 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation inhibitor
WO2000025809A1 (en) * 1998-10-30 2000-05-11 Smith & Nephew Plc Compositions comprising notch receptor manipulating agents
WO2003041735A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913404A1 (en) * 1996-07-16 1999-05-06 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation inhibitor
WO1998020142A1 (en) * 1996-11-07 1998-05-14 Lorantis Limited Notch
WO2000025809A1 (en) * 1998-10-30 2000-05-11 Smith & Nephew Plc Compositions comprising notch receptor manipulating agents
WO2003041735A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GRAY G E ET AL: "HUMAN LIGANDS OF THE NOTCH RECEPTOR", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 154, no. 3, March 1999 (1999-03-01), pages 785 - 794, XP000960906, ISSN: 0002-9440 *
HICKS C ET AL: "A SECRETED DELTA1-FC FUSION PROTEIN FUNCTIONS BOTH AS AN ACTIVATOR AND INHIBITOR OF NOTCH1 SIGNALING", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 68, no. 6, 15 June 2002 (2002-06-15), pages 655 - 667, XP009013890, ISSN: 0360-4012 *
JANG M-S ET AL: "NOTCH SIGNALING AS A TARGET IN MULTIMODALITY CANCER THERAPY", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 1, February 2000 (2000-02-01), pages 55 - 65, XP009013844, ISSN: 1464-8431 *
OSBORNE B ET AL: "Notch and the immune system", IMMUNITY, CELL PRESS, US, vol. 11, no. 6, December 1999 (1999-12-01), pages 653 - 663, XP002217474, ISSN: 1074-7613 *
See also references of EP1492816A2 *
SUN X ET AL: "SECRETED FORMS OF DELTA AND SERRATE DEFINE ANTAGONISTS OF NOTCH SIGNALING IN DROSOPHILA", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 124, no. 17, 1997, pages 3439 - 3448, XP002925005, ISSN: 0950-1991 *
ZLOBIN A ET AL: "TOWARD THE RATIONAL DESIGN OF CELL FATE MODIFIERS: NOTCH SIGNALING AS A TARGET FOR NOVEL BIOPHARMACEUTICALS", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, BOCA RATON,FL, US, vol. 1, no. 1, July 2000 (2000-07-01), pages 83 - 106, XP008004456, ISSN: 1389-2010 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449303B2 (en) 2003-05-02 2008-11-11 Health Research, Inc. Use of JAG2 expression in diagnosis of plasma cell disorders

Also Published As

Publication number Publication date
WO2003087159A2 (en) 2003-10-23
AU2003226537A8 (en) 2003-10-27
EP1492816A2 (en) 2005-01-05
WO2003087159A8 (en) 2005-05-12
AU2003226537A1 (en) 2003-10-27
JP2006506322A (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2003087159A8 (en) Modulators of the notch signalling pathway and uses thereof in medical treatment
WO2005102335A3 (en) Methods of treating sleep disorders
AU2003300200A1 (en) Valve treatment catheter and methods
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003202196A1 (en) Devices and methods for heart valve treatment
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
AU2001288628A1 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
WO2002080952A3 (en) Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
WO2003059372A3 (en) Combined use of a glp-1 compound and a modulator of diabetic late complications
AU2003225160A1 (en) "biosensor for dialysis therapy"
AU2003300791A1 (en) Combination therapy for the treatment of pain
WO2002084298A3 (en) Medicaments which are modulators of hm74 and/or hm74a activity
DE60324427D1 (en) METHOD FOR MODULATING TUBULINDEACETYLASE ACTIVITY
AUPR839001A0 (en) Dosage form, device and methods of treatment
WO2003030927A3 (en) Use of thymulin-like peptides for making pain-relieving medicines
AU2003280262A1 (en) Individualization of therapy with anticoagulants
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
EP1440691A3 (en) Treatment of neurotic disorders
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
AU2003227944A1 (en) Ddah modulators in the treatment of pain
WO2005007876A3 (en) Modulation of interleukin-10 by dhea
WO2006041409A8 (en) Medical solution, method for producing and use thereof
WO2001043697A3 (en) Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
PT1530462E (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10958784

Country of ref document: US

Ref document number: 2003584114

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003746366

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003746366

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 43/2003 UNDER (30) REPLACE "PCT/GB2/03397 AND PCT/GB2/03426" BY "PCT/GB2002/003397 AND PCT/GB2002/003426"